Abstract 2497
Background
Chemotherapy (CT) near end of life is considered a marker of inadequate palliative care for cancer patients. The objectives of our work were to determine the influence of palliative care at home and the distance between the residence area and the cancer referral center on the interval between last chemotherapy cycle and death.
Methods
A retrospective observational study was conducted in a tertiary care hospital. All cancer patients deceased between January 2013 and June 2014 were included. Clinical, demographical and treatment variables were obtained from medical records.
Results
Our population of 951 patients had a mean age of 63 years; male: 601 (63%), females: 350 (37%). Tumor locations: lung, 261 (28%); colorectal, 125 (13%); breast, 99 (10.7%); pancreas, 79 (8.8%). The table shows an analysis of the CT used in all patients, indicating a high proportion of CT use near the end of life (68% in the last 3 months). Average time elapsed between the end of treatment and death was significantly longer in the group of patients included in home palliative care programs (n = 111; 24.5%) vs. those not included (n = 367; 75.5%): 42.3 vs. 24.7 days (p < 0.05). CT was stopped earlier in patients belonging to geographical areas farther from the referral center, with median times between last cycle of CT and death of 14.9 days for patients living near the referral hospital versus 51.9 days for > 70 km (p = 0.041) and 58 days for > 100 km (p = 0.013).Table: 1522P
Analysis of CT use in all patients
| N = 901 | n (%) |
|---|---|
| Treatment No CT CT | 198 (22) 703 (78) |
| Nr of lines of CT 1 2 3 4 or more | 441 (49) 198 (22) 135 (15) 127 (14) |
| Nr of drugs in last line of CT 1 2 3 | 378 (42) 414 (46) 109 (12) |
| CT in the last 3 months | 604 (67) |
| CT in the last 4 weeks | 405 (45) |
| CT in the last week | 63 (7) |
Conclusions
In our population, a high percentage of CT was observed in the final stages of life, including a high use of third and successive lines of treatment. Patients included in home palliative care programs and/or belonging to more distant geographical areas finished active treatment before, thereby suggesting that both factors impact on decision making for patients with advanced cancer. Understanding the factors that determine the use of CT near the end of life may contribute to limit its inadequate indication.
Clinical trial identification
Legal entity responsible for the study
Hospital Universitario Santa Lucia, Cartagena.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4742 - Ki67 as an important predictor for Oncotype Dx Recurrence score risk groups in Early Breast cancer
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4697 - Genetic signatures always suggest undertreatment? Experience with PAM51
Presenter: Carolina Sales
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3158 - Significance of receptors expression, mitotic index and Ki67 in breast cancer patients with Nottingham Prognostic Index (NPI) poor prognosis score
Presenter: Mejri Nesrine
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3838 - Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients
Presenter: Javier Cortes Castan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
715 - Autoimmunity and benefit from trastuzumab treatment in breast cancer: results from the HERA phase 3 trial
Presenter: Amir Sonnenblick
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2388 - Impact of hormone receptor status in HER2+ early breast cancer: a paradigm shift in the trastuzumab era
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3742 - Sefety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The french HERMIONE non-interventional prospective study
Presenter: jean-philippe Jacquin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3647 - Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer.
Presenter: Rita De Sanctis
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3837 - Comprehensive evaluation of the pharmacokinetic profiles of SB3 and reference trastuzumab
Presenter: Xavier Pivot
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1692 - The impact of neoadjuvant dual HER2 targeting with Pertuzumab and Trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience
Presenter: Samantha Forner
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract